Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie nowotwór litych części ciała z brakiem genu MTAP w tkance guza
- •Guz jest nieoperacyjny lub ma przerzuty do innych miejsc
- •Wiek co najmniej 18 lat
- •Dobra ogólna kondycja fizyczna (stan wydolności 0 lub 1)
- •Prawidłowe funkcje narządów wewnętrznych
- •Dostępny guz do pobrania próbki tkanki
✗ Disqualifies
- •Wcześniejsze leczenie inhibitorami PRMT5 lub MAT2A
- •Przerzuty do mózgu lub zapalenie opon mózgowych spowodowane nowotworem
- •Krwawienie z dróg oddechowych lub znaczne krwawienie w ciągu 4 tygodni przed rozpoczęciem leczenia
- •Poważna operacja w ciągu 4 tygodni przed rozpoczęciem badania
- •Choroby przewodu pokarmowego, w tym niekontrolowana nudności, wymioty lub zaburzenia wchłaniania
- •Zaburzenia pracy serca
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (25)
Mayo Clinic
Phoenix, United States
Rocky Mountain Cancer Centers, LLP - Oncology
Lone Tree, United States
Mayo Clinic
Jacksonville, United States
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando, United States
Local Institution - 124
Chicago, United States
Dana-Farber Cancer Institute
Brookline, United States
The Cancer & Hematology Centers
Grand Rapids, United States
Cancer and Hematology Centers of Western Michigan
Norton Shores, United States
Mayo Clinic
Rochester, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, United States
Perlmutter Cancer Center at NYU Langone Hospital Long Island
Mineola, United States
David H Koch, Memorial Sloan Kettering Cancer Center
New York, United States
New york cancer and blood specialists - Oncology
Port Jefferson Station, United States
New york cancer and blood specialists - Oncology
Port Jefferson Station, United States
University of North Carolina - Gastroenterology and Hepatology
Chapel Hill, United States
University of North Carolina
Chapel Hill, United States
Vanderbilt - Ingram Cancer Center
Nashville, United States
Ut Southwestern
Dallas, United States
Texas Oncology - DFW
Fort Worth, United States
MDACC
Houston, United States
South Texas Accelerated Research Therapeutics
San Antonio, United States
Texas Oncology, P.A. - Oncology
Tyler, United States
Virginia Cancer Specialists, PC
Fairfax, United States
Local Institution - 134
Seattle, United States
Local Institution - 108
Milwaukee, United States
Trial contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
First line of the email MUST contain NCT # and Site #.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.